Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab combinations in advanced esophageal cancer
NCT05342636Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2022
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 2, randomised, open-label trial of favezelimab in Esophageal Squamous Cell Carcinoma (ESCC) (4 arms), sponsored by Merck & Co. Primary endpoints: Dose-limiting Toxicity at 3 weeks, Adverse Event at 3 weeks and 2 more. Started Jul 2022; status: completed.
02
Drugs
favezelimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05342636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05342636.